Andrew Fowell

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

Eleonora Scorletti, Lokpal Bhatia, Keith McCormick et al. · Hepatology · 2014 · 310 citations

Medicine, Nutritional Sciences, Pharmacology +17

Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease

Eleonora Scorletti, Paul R. Afolabi, Elizabeth A. Miles et al. · Gastroenterology · 2020 · 221 citations · Full text

Life Sciences, Microbiology, Microbial Ecology +14

Consistent beneficial effects of killer cell immunoglobulin‐like receptor 2DL3 and group 1 human leukocyte antigen‐C following exposure to hepatitis C virus†

Susanne Knapp, U. Warshow, Doha Hegazy et al. · Hepatology · 2009 · 156 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17